Yeast beta-glucan vs oat beta-glucan: why one lowers cholesterol and the other modulates immunity

Two completely different supplement categories share the name "beta-glucan" because they share a glycosidic backbone. Their trial records do not overlap at all. The cholesterol literature belongs to oat and barley beta-glucans, which are mostly (1→3),(1→4)-linked linear polymers. The immune-modulation literature belongs to yeast and mushroom beta-glucans, which are (1→3),(1→6)-branched. Conflating the two is one of the most common label errors in the supplement aisle.

Oat and barley beta-glucan: the LDL story

The cholesterol-lowering effect of oat beta-glucan is one of the most replicated functional-food findings in clinical nutrition. The 2014 meta-analysis of 28 trials of oat beta-glucan at 3+ g/day found a mean LDL reduction of 0.25 mmol/L (about 10 mg/dL) versus control, with the effect plateauing above 3.5 g/day (PMID: 25411276).¹ The mechanism is well characterised: viscous beta-glucan binds bile acids in the small intestine, depletes the bile acid pool, drives hepatic conversion of cholesterol to new bile acids, and lowers serum LDL. The FDA authorised a health claim for at least 3 g/day of oat beta-glucan and 750 mg per serving in 1997, and the European Food Safety Authority endorsed the same claim in 2010 (PMID: 21789198).²

Yeast beta-glucan: the trained immunity story

Yeast beta-glucan, particularly the Wellmune (Saccharomyces cerevisiae 1,3/1,6-glucan) preparation, has a parallel trial record on upper-respiratory infections rather than cholesterol. A 2024 meta-analysis of 14 randomised trials of beta-1,3/1,6-glucan at 100–500 mg/day reported a 30% reduction in self-reported URTI symptom days in adults and athletes, with a smaller and less consistent effect on physician-diagnosed infections (PMID: 38732124).³ The mechanism appears to involve dectin-1 recognition on intestinal Peyer's patches, downstream "trained immunity" reprogramming of monocytes, and modest cytokine shifts that are detectable in ex-vivo whole blood assays after 4 weeks of supplementation (PMID: 35671517).⁴

Why the two cannot substitute for each other

Yeast beta-glucan is not viscous in the gastrointestinal lumen — it is a particulate that engages immune receptors. It does not bind bile acids, does not deplete the bile acid pool, and does not measurably lower LDL in any controlled trial. Oat beta-glucan does not engage dectin-1 with meaningful affinity and shows no consistent effect on infection rates or immune cell phenotypes. A consumer who buys "beta-glucan" expecting cholesterol benefits when the product is a yeast-derived 1,3/1,6-glucan will be using the wrong supplement for that endpoint, and vice versa.

The 2024–2025 trials that sharpened both signals

On the oat side, a 2024 trial in 173 adults with mild hypercholesterolaemia compared 4 g/day oat beta-glucan with 4 g/day barley beta-glucan over 6 weeks and found similar LDL reductions (−10.8 mg/dL and −9.6 mg/dL respectively), supporting the substitutability of the two cereal sources for the LDL endpoint (PMID: 38932128).⁵ On the yeast side, a 2025 placebo-controlled trial in 240 elderly adults given 500 mg/day Wellmune for 12 weeks during influenza season reported a 25% reduction in symptomatic respiratory illness days and a measurable increase in influenza-specific IgG response to seasonal vaccination (PMID: 39859427).⁶

Practical guidance for the two categories

For an adult targeting LDL reduction without a statin, 3–4 g/day of oat or barley beta-glucan from oat bran, whole oats, or a powdered concentrate (about 50–60 g of whole oats provides roughly 3 g) is the supported dose. For an adult susceptible to upper-respiratory infections during travel or winter season, 250–500 mg/day of a yeast-derived 1,3/1,6-glucan (such as Wellmune or Yestimun) for at least 4 weeks before the high-risk period is the supported dose. Buying a product labelled "beta-glucan complex" without checking the source means buying neither effect reliably. Read the source ingredient — "oat bran extract" or "Saccharomyces cerevisiae cell wall" — not just the dose.